Latest News and Press Releases

ALK (ALKB:DC / OMX: ALK B) har i dag annonceret, at selskabets europæiske registreringsansøgning for ACARIZAX® (tabletvaccine mod husstøvmideallergi) hos børn i alderen fem til 11 år er blevet...

ALK (ALKB:DC / OMX: ALK B) today announced that its European regulatory filing for ACARIZAX® (house dust mite sublingual allergy immunotherapy tablet) in young children aged five to 11 has been...

The reputable scientific journal, The Lancet Regional Health – Europe, has published robust results from ALK’s house dust mite sublingual allergy immunotherapy tablet (SLIT-tablet) phase 3 children...

Company release No. 19/2024 ALK delivers 18% organic revenue growth and an operating profit margin of 23% in Q3 Revenue growth was mainly driven by a continued strong momentum in tablet sales...

Company release No. 19/2024 ALK delivers 18% organic revenue growth and an operating profit margin of 23% in Q3 Revenue growth was mainly driven by a continued strong momentum in tablet...

ALK (ALKB:DC / OMX: ALK B) har i dag annonceret, at selskabet har indgået en strategisk licensaftale med USA-baserede ARS Pharmaceuticals, Inc. (”ARS Pharma”) (NASDAQ: SPRY). Aftalen giver ALK...

ALK (ALKB:DC / OMX: ALK B) today announced that it has entered into a strategic license agreement with US-based ARS Pharmaceuticals, Inc. (“ARS Pharma”, NASDAQ: SPRY). The agreement grants ALK...

ALK (ALKB:DC / OMX: ALK B / AKBLF) offentliggør delårsrapport for de første ni måneder (Q3) af 2024 om morgenen torsdag den 14. november 2024. ALK afholder senere samme dag kl. 13.30 (CET) en...

ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its results for the first nine months (Q3) 2024 in the morning of Thursday 14 November 2024. Later same day, the company will host a presentation for...

ALK (ALKB:DC / OMX: ALK B / AKBLF): I henhold til artikel 19 i EU forordning nr. 596/2014 af 16. april 2014 om markedsmisbrug (markedsmisbrugsforordningen), følger hermed indberetning af ledende...